Skip to main content

Using Canine Osteosarcoma as a Model to Assess Efficacy of Novel Therapies: Can Old Dogs Teach Us New Tricks?

  • Chapter
  • First Online:
Current Advances in Osteosarcoma

Abstract

Since its domestication more than 10,000 years ago, the dog has been the animal that most intimately shares our work and homelife. Interestingly, the dog also shares many of our diseases including cancer such as osteosarcoma. Like the human, osteosarcoma is the most common bone malignancy of the dog and death from pulmonary metastasis is the most common outcome. The incidence of this spontaneous bone neoplasm occurs ten times more frequently that it does so in children with about 8,000–10,000 cases estimated to occur in dogs in the USA. Because there is no “standard of care” in veterinary medicine, the dog can also serve us by being a model for this disease in children. Although the most common therapy for the dog with osteosarcoma is amputation followed by chemotherapy, not all owners choose this route. Consequently, novel therapeutic interventions can be attempted in the dog with or without chemotherapy that could not be done in humans with osteosarcoma due to ethical concerns. This chapter will focus on the novel therapies in the dog that have been reported or are in veterinary clinical trials at the author’s institution. It is hoped that collaboration between veterinary oncologists and pediatric oncologists will lead to the development of novel therapies for (micro- or macro-) metastatic osteosarcoma that improve survival and might ultimately lead to a cure in both species.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson H, Lund B, Bach F et al (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung-cancer - A phase-II study. J Clin Oncol 12:1821–1826

    PubMed  CAS  Google Scholar 

  2. Anderson PM, Wiseman GA, Erlandson L et al (2005) Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 11:6895–6900

    Article  PubMed  CAS  Google Scholar 

  3. Ando T, Ichikawa J, Okamoto A et al (2005) Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 23:964–969

    Article  PubMed  CAS  Google Scholar 

  4. Bacon NJ, Ehrhart NR, Dernell WS et al (2008) Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). JAVMA 232:1504–1510

    Article  PubMed  CAS  Google Scholar 

  5. Bailey D, Erb H, Williams L et al (2003) Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 17:199–205

    Article  PubMed  Google Scholar 

  6. Batschinski K, Dervisis NG, Kitchell BE (2012) Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. Vet Comp Oncol. 2012 Sep 18. DOI: 10.1111/j.1476-5829.2012.00355

  7. Berg J, Gebhardt MC, Rand WM (1997) Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 79:1343–1350

    Article  PubMed  CAS  Google Scholar 

  8. Berg J, Weinstein MJ, Schelling SH et al (1992) Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 200:2005–2008

    PubMed  CAS  Google Scholar 

  9. Berg J, Weinstein MJ, Springfield DS et al (1995) Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 206:1555–1560

    PubMed  CAS  Google Scholar 

  10. Bergman PJ, Macewen EG, Kurzman ID et al (1996) Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 10:76–81

    Article  PubMed  CAS  Google Scholar 

  11. Bezault J, Walsh C, Tarcsay L et al (1993) Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. In Vivo 7:487–491

    PubMed  CAS  Google Scholar 

  12. Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790

    Article  PubMed  Google Scholar 

  13. Boston SE, Ehrhart NP, Dernell WS et al (2006) Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004). J Am Vet Med Assoc 228:1905–1908

    Article  PubMed  Google Scholar 

  14. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V et al (1991) Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. Arch Neurol 48:42–47

    Article  PubMed  CAS  Google Scholar 

  15. Brewer GJ, Merajver SD (2002) Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper – a review. Integr Cancer Ther 1:327–337

    Article  PubMed  CAS  Google Scholar 

  16. Chun R, Garrett LD, Henry C et al (2005) Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 41:382–387

    Article  PubMed  Google Scholar 

  17. Chun R, Kurzman ID, Couto CG et al (2000) Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med 14:495–498

    Article  PubMed  CAS  Google Scholar 

  18. Cox C, Teknos TN, Barrios M et al (2001) The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 111:696–701

    Article  PubMed  CAS  Google Scholar 

  19. Cozzi PJ, Bajorin DF, Tong W et al (1999) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5:2629–2637

    PubMed  CAS  Google Scholar 

  20. De Brito Galvao JF, Kisseberth WC, Murahari S et al (2012) Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines. Am J Vet Res 73:1262–1272

    Article  PubMed  Google Scholar 

  21. Dominguez PA, Dervisis NG, Cadile CD et al (2009) Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med 23:130–137

    Article  PubMed  CAS  Google Scholar 

  22. Duan X, Jia SF, Koshkina N et al (2006) Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106:1382–1388

    Article  PubMed  CAS  Google Scholar 

  23. Elpiner AK, Brodsky EM, Hazzah TN et al (2011) Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas. Vet Comp Oncol 9:260–268

    Article  PubMed  CAS  Google Scholar 

  24. Fidler IJ, Kleinerman ES (1984) Lymphokine-activated human-blood monocytes destroy tumor-cells but not normal-cells under cocultivation conditions. J Clin Oncol 2:937–943

    PubMed  CAS  Google Scholar 

  25. Fidler IJ, Schroit AJ (1988) Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948:151–173

    PubMed  CAS  Google Scholar 

  26. Fidler IJ, Sone S, Fogler WE et al (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous-injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A 78:1680–1684

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Fidler IJ, Sone S, Fogler WE et al (1982) Efficacy of liposomes containing a lipophilic muramyl di peptide derivative for activating the tumoricidal properties of alveolar macrophages in-vivo. J Biol Response Mod 1:43–56

    CAS  Google Scholar 

  28. Freise KJ, Martin-Jimenez T (2006) Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J Vet Pharmacol Ther 29:137–145

    Article  PubMed  CAS  Google Scholar 

  29. Freise KJ, Martin-Jimenez T (2006) Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther 29:147–152

    Article  PubMed  CAS  Google Scholar 

  30. Funk J, Schmitz G, Failing K et al (2005) Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother 54:87–92

    Article  PubMed  CAS  Google Scholar 

  31. Gagnadoux F, Leblond V, Vecellio L et al (2006) Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer chemotherapy and pharmacology 58:237–244

    Article  PubMed  CAS  Google Scholar 

  32. Gandhi V, Plunkett W, Du M et al (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665–673

    Article  PubMed  CAS  Google Scholar 

  33. Gordon N, Arndt CS, Hawkins DS et al (2005) Fas expression in lung metastasis from osteosarcoma patients. J Pediat Hematol Oncol 27:611–615

    Article  Google Scholar 

  34. Gordon N, Koshkina NV, Jia S-F et al (2007) Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13:4503–4510

    Article  PubMed  CAS  Google Scholar 

  35. Grunewald R, Kantarjian H, Du M et al (1992) Gemcitabine in leukemia - a phase-I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413

    PubMed  CAS  Google Scholar 

  36. Guma SR, Lee DA, Yu L et al (2013) Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediat Blood Cancer 61(4):618–626

    Article  CAS  Google Scholar 

  37. Helfand SC, Soergel SA, Macwilliams PS et al (1994) Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs. Cancer Immunol Immunother 39:84–92

    Article  PubMed  CAS  Google Scholar 

  38. Hershey AE, Kurzman ID, Forrest LJ et al (1999) Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 5:2653–2659

    PubMed  CAS  Google Scholar 

  39. Herzog CE (2005) Overview of sarcomas in the adolescent and young adult population. J Pediat Hematol Oncol 27:215–218

    Article  Google Scholar 

  40. Hibbs JB (1974) Discrimination between neoplastic and non-neoplastic cells invitro by activated macrophages. J Natl Cancer Inst 53:1487–1492

    PubMed  Google Scholar 

  41. Hillers KR, Dernell WS, Lafferty MH et al (2005) Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986-2003). J Am Vet Med Assoc 226:1364–1367

    Article  PubMed  Google Scholar 

  42. Huang P, Chubb S, Hertel LW et al (1991) Action of 2′,2′-difluorodeoxycytidine on dna-synthesis. Cancer Res 51:6110–6117

    PubMed  CAS  Google Scholar 

  43. Huland E, Heinzer H, Jorres RA et al (2004) Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy. Der Urologe Ausg A 43(Suppl 3):S140–S144

    PubMed  Google Scholar 

  44. Jones PD, De Lorimier LP, Kitchell BE et al (2003) Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 39:463–467

    Article  PubMed  Google Scholar 

  45. Jongeward SJ (1985) Primary bone-tumors. Vet Clin Small Anim Pract 15:609–641

    CAS  Google Scholar 

  46. Kawai M, Esumi Y, Ishizaki M et al (1995) Metabolism of gemcitabine in rat and dog. Xenobiotica 25:405–416

    Article  PubMed  CAS  Google Scholar 

  47. Kent MS, Strom A, London CA et al (2004) Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med 18:540–544

    Article  PubMed  Google Scholar 

  48. Khan MK, Miller MW, Taylor J et al (2002) Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4:164–170

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Khanna C, Hasz DE, Klausner JS et al (1996) Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 2:721–734

    PubMed  CAS  Google Scholar 

  50. Khanna C, Waldrep JC, Anderson PM et al (1997) Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol 49:960–971

    Article  PubMed  CAS  Google Scholar 

  51. Kim KK, Kawar NM, Singh RK et al (2011) Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecol Oncol 122:183–189

    Article  PubMed  CAS  Google Scholar 

  52. Kleinerman ES, Erickson KL, Schroit AJ et al (1983) Activation of tumoricidal properties in human-blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43:2010–2014

    PubMed  CAS  Google Scholar 

  53. Kleinerman ES, Gano JB, Johnston DA et al (1995) Efficacy of liposomal muramyl tripeptide (Cgp 19835a) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18:93–99

    Article  PubMed  CAS  Google Scholar 

  54. Kleinerman ES, Jia SF, Griffin J et al (1992) Phase-II study of liposomal muramyl tripeptide in osteosarcoma - the cytokine cascade and monocyte activation following administration. J Clin Oncol 10:1310–1316

    PubMed  CAS  Google Scholar 

  55. Kleinerman ES, Murray JL, Snyder JS et al (1989) Activation of tumoricidal properties in monocytes from cancer-patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49:4665–4670

    PubMed  CAS  Google Scholar 

  56. Kosarek CE, Kisseberth WC, Gallant SL et al (2005) Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 19:81–86

    Article  PubMed  Google Scholar 

  57. Koshkina NV, Khanna C, Mendoza A et al (2007) Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 5:991–999

    Article  PubMed  CAS  Google Scholar 

  58. Koshkina NV, Kleinerman ES (2005) Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 116:458–463

    Article  PubMed  CAS  Google Scholar 

  59. Koshkina NV, Waldrep JC, Roberts LE et al (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–3262

    PubMed  CAS  Google Scholar 

  60. Kozicki AR, Robat C, Chun R et al (2013) Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma. Vet Comp Oncol. 10 MAY 2013, DOI: 10.1111/vco.12040

  61. Kraegel SA, Madewell BR, Simonson E et al (1991) Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 199:1057–1059

    PubMed  CAS  Google Scholar 

  62. Kurzman ID, Macewen EG, Rosenthal RC et al (1995) Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1:1595–1601

    PubMed  CAS  Google Scholar 

  63. Kurzman ID, Shi F, Macewen EG (1993) In-vitro and in-vivo canine mononuclear cell production of tumor-necrosis-factor induced by muramyl peptides and lipopolysaccharide. Vet Immunol Immunopathol 38:45–56

    Article  PubMed  CAS  Google Scholar 

  64. Lafleur EA, Koshkina NV, Stewart J et al (2004) Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 10:8114–8119

    Article  PubMed  CAS  Google Scholar 

  65. Leblanc AK, Ladue TA, Turrel JM et al (2004) Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 45:466–470

    Article  PubMed  Google Scholar 

  66. Lemarie E, Vecellio L, Hureaux J et al (2011) Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv 24:261–270

    Article  PubMed  CAS  Google Scholar 

  67. Macewen EG, Kurzman ID, Rosenthal RC et al (1989) Therapy for osteo-sarcoma in dogs with intravenous-injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81:935–938

    Article  PubMed  CAS  Google Scholar 

  68. Madewell BR, Leighton RL, Theilen GH (1978) Amputation and doxorubicin for treatment of canine and feline osteogenic-sarcoma. Eur J Cancer 14:287–293

    Article  PubMed  CAS  Google Scholar 

  69. Maeda M, Knowles RD, Kleinerman ES (1991) Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor-necrosis-factor and interleukin-1 invitro. Cancer Commun 3:313–321

    PubMed  CAS  Google Scholar 

  70. Marchi E, Alinari L, Tani M et al (2005) Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 104:2437–2441

    Article  PubMed  CAS  Google Scholar 

  71. Marconato L, Lorenzo RM, Abramo F et al (2008) Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 6:90–101

    Article  PubMed  CAS  Google Scholar 

  72. Marconato L, Zini E, Lindner D et al (2011) Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 238:1004–1010

    Article  PubMed  CAS  Google Scholar 

  73. Mauldin GN, Matus RE, Withrow SJ et al (1988) Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 2:177–180

    Article  PubMed  CAS  Google Scholar 

  74. Mcmahon M, Mathie T, Stingle N et al (2011) Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet Intern Med 25:511–517

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  75. Mcmahon MB, Bear MD, Kulp SK et al (2010) Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. Am J Vet Res 71:799–808

    Article  PubMed  CAS  Google Scholar 

  76. Merimsky O, Meller I, Flusser G et al (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45:177–181

    Article  PubMed  CAS  Google Scholar 

  77. Merimsky O, Meller I, Kollender Y et al (1998) Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer 34:1296–1297

    Article  PubMed  CAS  Google Scholar 

  78. Merimsky O, Meller I, Kollender Y et al (2000) Gemcitabine in bone sarcoma resistant to Doxorubicin-based chemotherapy. Sarcoma 4:7–10

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  79. Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol 26:633–638

    Article  PubMed  CAS  Google Scholar 

  80. Morello E, Buracco P, Martano M et al (2001) Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract 42:61–66

    Article  PubMed  CAS  Google Scholar 

  81. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007–1008

    Article  PubMed  CAS  Google Scholar 

  82. Mule JJ, Yang JC, Afreniere RL et al (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139:285–294

    PubMed  CAS  Google Scholar 

  83. Navid F, Willert JR, Mccarville MB et al (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113:419–425

    Article  PubMed  CAS  Google Scholar 

  84. O’brien MG, Straw RC, Withrow SJ et al (1993) Resection of pulmonary metastases in canine osteosarcoma: 36 cases (1983-1992). Vet Surg 22:105–109

    Article  PubMed  Google Scholar 

  85. Okuno S, Edmonson J, Mahoney M et al (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225–3229

    Article  PubMed  CAS  Google Scholar 

  86. Okuno S, Ryan LM, Edmonson JH et al (2003) Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97:1969–1973

    Article  PubMed  CAS  Google Scholar 

  87. Pan Q, Kleer CG, Van Golen KL et al (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854–4859

    PubMed  CAS  Google Scholar 

  88. Paoloni M, Davis S, Lana S et al (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10:625

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Papa MZ, Mule JJ, Rosenberg SA (1986) Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res 46:4973–4978

    PubMed  CAS  Google Scholar 

  90. Parke A, Bhattacherjee P, Palmer RM et al (1988) Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 130:173–178

    PubMed  CAS  PubMed Central  Google Scholar 

  91. Perez-Manga G, Lluch A, Alba E et al (2000) Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 18:2545–2552

    PubMed  CAS  Google Scholar 

  92. Phillips B, Powers BE, Dernell WS et al (2009) Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 45:33–38

    Article  PubMed  Google Scholar 

  93. Raju KS, Alessandri G, Ziche M et al (1982) Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 69:1183–1188

    PubMed  CAS  Google Scholar 

  94. Rizzieri DA, Bass AJ, Rosner GL et al (2002) Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 20:674–679

    Article  PubMed  CAS  Google Scholar 

  95. Rizzieri DA, Ibom VK, Moore JO et al (2003) Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res 9:663–668

    PubMed  CAS  Google Scholar 

  96. Rodriguez CO, Crabbs TA, Wilson DW et al (2010) Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 23:197–206

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  97. Rosenberg SA, Mule JJ, Spiess PJ et al (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169–1188

    Article  PubMed  CAS  Google Scholar 

  98. Saam DE, Liptak JM, Stalker MJ et al (2011) Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). J Am Vet Med Assoc 238:195–206

    Article  PubMed  Google Scholar 

  99. Santoro A, Bredenfeld H, Devizzi L et al (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18:2615–2619

    PubMed  CAS  Google Scholar 

  100. Selting K, Essman S, Reinero C et al (2011) Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading. J Aerosol Med Pulm Drug Deliv 24:43–48

    Article  PubMed  CAS  Google Scholar 

  101. Shapiro W, Fossum TW, Kitchell BE et al (1988) Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 192:507–511

    PubMed  CAS  Google Scholar 

  102. Shi FS, Macewen EG, Kurzman ID (1993) In-vitro and in-vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res 53:3986–3991

    PubMed  CAS  Google Scholar 

  103. Shipley LA, Brown TJ, Cornpropst JD et al (1992) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849–855

    PubMed  CAS  Google Scholar 

  104. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9:694–704

    PubMed  CAS  Google Scholar 

  105. Simcock JO, Withers SS, Prpich CY et al (2012) Evaluation of a single subcutaneous infusion of carboplatin as adjuvant chemotherapy for dogs with osteosarcoma: 17 cases (2006-2010). J Am Vet Med Assoc 241:608–614

    Article  PubMed  CAS  Google Scholar 

  106. Skorupski KA, Uhl JM, Szivek A et al (2013) Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. Vet Comp Oncol. 2013 Oct 4. DOI: 10.1111/vco.12069

  107. Smith BW, Kurzman ID, Schultz KT et al (1993) Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother 8:137–144

    Article  PubMed  CAS  Google Scholar 

  108. Smith MA, Seibel NL, Altekruse SF et al (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28:2625–2634

    Article  PubMed  PubMed Central  Google Scholar 

  109. Spodnick GJ, Berg J, Rand WM et al (1992) Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 200:995–999

    PubMed  CAS  Google Scholar 

  110. Straw RC, Withrow SJ, Richter SL et al (1991) Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 5:205–210

    Article  PubMed  CAS  Google Scholar 

  111. Thompson JP, Fugent MJ (1992) Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 200:531–533

    PubMed  CAS  Google Scholar 

  112. Turner AI, Hahn KA, Rusk A et al (2006) Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 20:1384–1388

    Article  PubMed  Google Scholar 

  113. Vail DM, Kurzman ID, Glawe PC et al (2002) STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 50:131–136

    Article  PubMed  CAS  Google Scholar 

  114. Van Golen KL, Bao L, Brewer GJ et al (2002) Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 4:373–379

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Van Moorsel CJ, Peters GJ, Pinedo HM (1997) Gemcitabine: future prospects of single-agent and combination studies. Oncologist 2:127–134

    PubMed  Google Scholar 

  116. Vial T, Descotes J (1992) Clinical toxicity of interleukin-2. Drug Saf 7:417–433

    Article  PubMed  CAS  Google Scholar 

  117. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP et al (2006) Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 17:859–864

    Article  PubMed  CAS  Google Scholar 

  118. Withrow SJ, Thrall DE, Straw RC et al (1993) Intraarterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71:2484–2490

    Article  PubMed  CAS  Google Scholar 

  119. Worth LL, Lafleur EA, Jia SF et al (2002) Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9:823–827

    PubMed  CAS  Google Scholar 

  120. Zak D, Styler MJ, Rosenbluth JZ et al (2005) Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma. Clin Adv Hematol Oncol 3:297–299, discussion 300-292

    PubMed  Google Scholar 

  121. Zinzani PL, Baliva G, Magagnoli M et al (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603–2606

    PubMed  CAS  Google Scholar 

  122. Zinzani PL, Bendandi M, Stefoni V et al (2000) Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica 85:926–929

    PubMed  CAS  Google Scholar 

  123. Zinzani PL, Magagnoli M, Bendandi M et al (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351–1353

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlos O. Rodriguez Jr. D.V.M., Ph.D., D.A.C.V.I.M. (Oncology) .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Rodriguez, C.O. (2014). Using Canine Osteosarcoma as a Model to Assess Efficacy of Novel Therapies: Can Old Dogs Teach Us New Tricks?. In: Kleinerman, M.D., E. (eds) Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, vol 804. Springer, Cham. https://doi.org/10.1007/978-3-319-04843-7_13

Download citation

Publish with us

Policies and ethics